NCI-H1373

NCI-H1373 (Lung Cancer CDX Model) 

The NCI-H1373 cell line was derived from a non-small cell lung carcinoma (NSCLC). It carries a KRAS mutation, representing a frequent driver of NSCLC progression. The model provides reproducible tumor growth in xenografts. Its defined mutation status makes it highly relevant for targeted therapy research. 

Key Features: 

• Derived from non-small cell lung carcinoma. 

• KRAS-mutant NSCLC model. 

• Epithelial morphology. 

• Tumorigenic in xenografts. 

Applications: 
NCI-H1373 is used in drug discovery for KRAS-driven NSCLC. Researchers apply it in targeted therapy and biomarker validation studies. It supports resistance mechanism evaluation in lung cancer. Its reproducibility makes it a valuable tool in translational oncology pipelines.